What is the endpoint for [B032] Drug clinical result basic information?

The [B032] Drug clinical result basic information endpoint is GET https://connect.patsnap.com/synapse/ct-result/detail.

What data can [B032] Drug clinical result basic information return?

[B032] Drug clinical result basic information Obtain clinical result data through clinical result ID. See the Response Schema and Success Response Example on this page for the full structure.

Where can I find the OpenAPI schema for [B032] Drug clinical result basic information?

The OpenAPI schema is available at /openapi.json#/paths/~1synapse~1ct-result~1detail/get. You can also browse the full specification at /openapi.json.

[B032] Drug clinical result basic information

get

https://connect.patsnap.com/synapse/ct-result/detail

Try in Sandbox

Obtain clinical result data through clinical result ID

Request Parameters

List of parameters supported by this API endpoint

Name	Type	Example	Description
`ct_result_id`	`string`	`e8ea588d3590e929a8022420da25d555`	Clinical trial result ID, obtain this through clinical result search interface

Response Schema

Structure of the API response data

Field Name	Type	Example	Description
`data`	`object`	-	response data
`drug`	`array`	`[ { "drug_id": "2838b95ade834c96b17ac8bcd2b68c27", "display_name": [ { "lang": "EN", "name": "Sotorasib" }, { "lang": "CN", "name": "索托拉西布" } ] } ]`	Drug
`drug_id`	`string`	`e82b83b42eba4e5ea3f26f8e06081a5a`	Drug ID
`display_name`	`array`	`[ { "lang": "EN", "name": "Ranibizumab (Genentech)" }, { "lang": "CN", "name": "雷珠单抗" } ]`	Drug Name, Referencing "CommonName"
`lang`	`string`	`EN`	Language
`name`	`string`	`Ranibizumab (Genentech)`	Drug,Target,Organization,Disease,Country/Location,DICT,Mechanism Action Name
`phase`	`object`	`{ "display_name": [ { "lang": "EN", "name": "Not Applicable" }, { "lang": "CN", "name": "N/A" } ], "normalized_id": "ab5cf80923724fe3964bf485b1ba13fe" }`	Phase
`display_name`	`array`	`[ { "lang": "EN", "name": "Autologous CAR-T" }, { "lang": "CN", "name": "自体CAR-T" } ]`	Dict Name
`normalized_id`	`string`	`2fbfdb3e92d942c48cbb0adb79f23526`	Dict ID
`title`	`string`	`Matching-Adjusted Indirect Treatment Comparisons (MAIC) of Sotorasib 960mg (soto960) Plus Panitumumab (pani) Vs. Trifluridine/Tipiracil(T/T) Plus Bevacizumab (bev) in Chemorefractory Metastatic Colorectal Cancer (mCRC)`	title
`target`	`array`	`[ { "target_id": "8556307199154d34b1f9bc9685f2ec47", "short_name": [ { "lang": "EN", "name": "IL-6RA" } ], "display_name": [ { "lang": "EN", "name": "Interleukin-6 receptor alpha subunit" }, { "lang": "CN", "name": "白细胞介素-6受体α亚基" } ] } ]`	Target
`target_id`	`string`	`1c2067e5ab054a8995f73efcfcf56207`	Target ID
`short_name`	`array`	`[ { "lang": "EN", "name": "VEGF" } ]`	Target Short Name, Referencing "CommonName"
`display_name`	`array`	`[ { "lang": "EN", "name": "Vascular endothelial growth factor" }, { "lang": "CN", "name": "血管内皮生长因子" } ]`	Target Full Name, Referencing "CommonName"
`biomarker`	`array`	`[ { "id": "11acf267a4fc42f392751e023482aac3", "display_name": [ { "lang": "EN", "name": "CTNNB1 Mutation" } ] } ]`	Biomarker Id
`id`	`string`	`11acf267a4fc42f392751e023482aac3`	ID
`display_name`	`array`	`[ { "lang": "EN", "name": "CTNNB1 Mutation" } ]`	Name, Referencing "CommonName"
`conclusion`	`string`	`Sotorasib-panitumumab demonstrated acceptable safety with promising efficacy in chemotherapy-refractory KRASG12C-mutated metastatic colorectal cancer.`	Conclusion
`related_id`	`array`	`[ { "id_type": "study_identifier", "id_value": "CodeBreaK 300" } ]`	Study code
`id_type`	`string`	`study_identifier`	ID type, study_identifier:Trial Code
`id_value`	`string`	`DESTINY-Breast04`	value
`ct_result_id`	`string`	`5400a5a2dee3da90dd52408a3585d805`	Clinical Trial Result Id
`organization`	`array`	`[ { "display_name": [ { "lang": "EN", "name": "Amgen, Inc." }, { "lang": "CN", "name": "安进股份有限公司" } ], "organization_id": "11ef8a9e8bf5ca80213a1183511cded3" } ]`	Organization master entity id view
`display_name`	`array`	`[ { "lang": "EN", "name": "Roche Holding AG" }, { "lang": "CN", "name": "罗氏" } ]`	Organization Name, Referencing "CommonName"
`organization_id`	`string`	`87bfaf037f8e60c9e25595cd98bb27e4`	Organization ID
`study_design`	`object`	`{ "allocation_normalized": { "display_name": [ { "lang": "EN", "name": "Non-Randomized" }, { "lang": "CN", "name": "非随机化" } ], "normalized_id": "f2deb94314e73728bc13bedb47273b6b" }, "intervention_model_normalized": { "display_name": [ { "lang": "EN", "name": "Sequential Assignment" }, { "lang": "CN", "name": "序贯设计" } ], "normalized_id": "4c2fcb852d2837e883c15d260612e7c3" } }`	Study design
`masking`	`string`	`XXXX`	Masking
`allocation`	`string`	`XXXX`	Allocation
`primary_purpose`	`string`	`XXXX`	Primary Purpose
`intervention_model`	`string`	`XXXX`	Intervention Model
`allocation_normalized`	`object`	`Please check the form:ViewDto`	Allocation Detail
`intervention_model_normalized`	`object`	`Please check the form:ViewDto`	Intervention Model
`therapy_type`	`array`	`[ { "display_name": [ { "lang": "EN", "name": "Third line" }, { "lang": "CN", "name": "三线" } ], "normalized_id": "62662f0b1d5b3fafabeb571a211e9a31" } ]`	Therapy type view
`published_time`	`integer<int64>`	`1719446400000`	Publication Date
`register_number`	`array`	`[ "NCT05198934" ]`	Register number
`single_or_multi`	`string`	`single_drug`	Single or multi, options:single_drug,multiple_drugs
`mechanism_action`	`array`	`[ { "short_name": [ { "lang": "EN", "name": "IL-6RA antagonists" }, { "lang": "CN", "name": "IL-6RA拮抗剂" } ], "display_name": [ { "lang": "EN", "name": "Interleukin-6 receptor alpha subunit antagonists" }, { "lang": "CN", "name": "白细胞介素-6受体α亚基拮抗剂" } ], "mechanism_id": "b30a0bdb2e0bd9c03a908a84588c4217" } ]`	Mechanism Action
`short_name`	`array`	`[ { "lang": "EN", "name": "KRAS G12C inhibitors" }, { "lang": "CN", "name": "KRAS G12C抑制剂" } ]`	Mechanism Action Short Name
`display_name`	`array`	`[ { "lang": "EN", "name": "GTPase KRas G12C inhibitors" }, { "lang": "CN", "name": "KRAS G12C突变抑制剂" } ]`	Mechanism Action Name
`mechanism_id`	`string`	`27c0848a265e4332836e10d0e8202b4c`	Mechanism Action ID
`therapeutic_area`	`array`	`[ { "disease_id": "042cbe45c973477b957717ded29ef7b6", "display_name": [ { "lang": "EN", "name": "Nervous System Diseases" }, { "lang": "CN", "name": "神经系统疾病" } ] } ]`	Therapeutic Area
`disease_id`	`string`	`06a9082fe1ec4c97bea31d888b9cfdce`	Disease ID
`display_name`	`array`	`[ { "lang": "EN", "name": "Uveitic Macular Edema" }, { "lang": "CN", "name": "葡萄膜炎黄斑水肿" } ]`	Disease Name, Referencing "CommonName"
`condition_disease`	`array`	`[ { "disease_id": "e35ce4e9b7a846d49e600ce7ac4a7fd6", "display_name": [ { "lang": "EN", "name": "Metastatic Colorectal Carcinoma" }, { "lang": "CN", "name": "转移性结直肠癌" } ] } ]`	Condition Disease
`general_evaluation`	`object`	`{ "display_name": [ { "lang": "EN", "name": "Positive" }, { "lang": "CN", "name": "积极" } ], "normalized_id": "3289297424e03eda9b788c083bbf3147" }`	General Evaluation
`original_biomarker`	`array`	`[ { "name": "IL-6" } ]`	Original Biomarker
`overall_enrollment`	`integer<int32>`	`100`	Overall enrollment
`register_number_map`	`object`	`{ "NCT04737187": "5a4a2ad359d8a855d925943e23a58845" }`	Register number map
`sponsor_organization`	`array`	`[ { "display_name": [ { "lang": "EN", "name": "Amgen, Inc." }, { "lang": "CN", "name": "安进股份有限公司" } ], "organization_id": "11ef8a9e8bf5ca80213a1183511cded3" } ]`	Sponsor Organization
`collaborator_organization`	`array`	`[ { "display_name": [ { "lang": "EN", "name": "Amgen, Inc." }, { "lang": "CN", "name": "安进股份有限公司" } ], "organization_id": "11ef8a9e8bf5ca80213a1183511cded3" } ]`	Collaborator Organization
`status` Required	`boolean`	`false`	Status
`error_msg`	`string`	`The request parameter format is incorrect！`	Error Message
`error_code` Required	`integer`	`0`	Error Code

Success Response Example

Example of a successful API response

JSON

{
  "data": {
    "drug": [
      {
        "drug_id": "e82b83b42eba4e5ea3f26f8e06081a5a",
        "display_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ]
      }
    ],
    "phase": {
      "display_name": [
        {
          "lang": "EN",
          "name": "Ranibizumab (Genentech)"
        }
      ],
      "normalized_id": "2fbfdb3e92d942c48cbb0adb79f23526"
    },
    "title": "Matching-Adjusted Indirect Treatment Comparisons (MAIC) of Sotorasib 960mg (soto960) Plus Panitumumab (pani) Vs. Trifluridine/Tipiracil(T/T) Plus Bevacizumab (bev) in Chemorefractory Metastatic Colorectal Cancer (mCRC)",
    "target": [
      {
        "target_id": "1c2067e5ab054a8995f73efcfcf56207",
        "short_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ],
        "display_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ]
      }
    ],
    "biomarker": [
      {
        "id": "11acf267a4fc42f392751e023482aac3",
        "display_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ]
      }
    ],
    "conclusion": "Sotorasib-panitumumab demonstrated acceptable safety with promising efficacy in chemotherapy-refractory KRASG12C-mutated metastatic colorectal cancer.",
    "related_id": [
      {
        "id_type": "study_identifier",
        "id_value": "DESTINY-Breast04"
      }
    ],
    "ct_result_id": "5400a5a2dee3da90dd52408a3585d805",
    "organization": [
      {
        "display_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ],
        "organization_id": "87bfaf037f8e60c9e25595cd98bb27e4"
      }
    ],
    "study_design": {
      "masking": "XXXX",
      "allocation": "XXXX",
      "primary_purpose": "XXXX",
      "intervention_model": "XXXX",
      "allocation_normalized": {
        "display_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ],
        "normalized_id": "2fbfdb3e92d942c48cbb0adb79f23526"
      },
      "intervention_model_normalized": {
        "display_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ],
        "normalized_id": "2fbfdb3e92d942c48cbb0adb79f23526"
      }
    },
    "therapy_type": [
      {
        "display_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ],
        "normalized_id": "2fbfdb3e92d942c48cbb0adb79f23526"
      }
    ],
    "published_time": 1719446400000,
    "register_number": [
      "NCT05198934"
    ],
    "single_or_multi": "single_drug",
    "mechanism_action": [
      {
        "short_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ],
        "display_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ],
        "mechanism_id": "27c0848a265e4332836e10d0e8202b4c"
      }
    ],
    "therapeutic_area": [
      {
        "disease_id": "06a9082fe1ec4c97bea31d888b9cfdce",
        "display_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ]
      }
    ],
    "condition_disease": [
      {
        "disease_id": "06a9082fe1ec4c97bea31d888b9cfdce",
        "display_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ]
      }
    ],
    "general_evaluation": {
      "display_name": [
        {
          "lang": "EN",
          "name": "Ranibizumab (Genentech)"
        }
      ],
      "normalized_id": "2fbfdb3e92d942c48cbb0adb79f23526"
    },
    "original_biomarker": [
      {
        "lang": "EN",
        "name": "Ranibizumab (Genentech)"
      }
    ],
    "overall_enrollment": 100,
    "register_number_map": {
      "NCT04737187": "5a4a2ad359d8a855d925943e23a58845"
    },
    "sponsor_organization": [
      {
        "display_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ],
        "organization_id": "87bfaf037f8e60c9e25595cd98bb27e4"
      }
    ],
    "collaborator_organization": [
      {
        "display_name": [
          {
            "lang": "EN",
            "name": "Ranibizumab (Genentech)"
          }
        ],
        "organization_id": "87bfaf037f8e60c9e25595cd98bb27e4"
      }
    ]
  },
  "status": true,
  "error_code": 0
}

Error Codes

List of possible error codes returned by this endpoint

Business Errors

Error Code	Description
`68300004`	Invalid parameter!
`68300005`	Search api failure!
`68300006`	Analytic basic access error!
`68300007`	Bad request!
`68300008`	Service error, please try again later!
`68300010`	The file does not comply with upload specifications!

Platform Errors

Error Code	Description
`67200001`	API call exceeds the total limit set by the platform!
`67200002`	Quota exceeds the limit!
`67200003`	Access token expired or authentication error!
`67200004`	No permission or API package quota has exceeded the limit!
`67200005`	Insufficient balance, call failed!
`67200006`	This client has expired and call failed!
`67200007`	Exceeded the call limit, call failed!

HTTP Status Codes

Status Code	Description
`0`	Success
`401`	Unauthorized
`403`	Forbidden
`404`	Not Found

Performance Metrics

Expected performance characteristics for this endpoint

Normal Response Time

5000 ms

Max Response Time

10000 ms